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Abstract
Cardiac arrest causes generalized ischaemia/hypoxia, and subsequent resuscitation
inflicts reperfusion injury, the pathology of which is not fully understood.
Moreover, predicting the prognosis of comatose, post-cardiac arrest patients is a
complex clinical challenge. We hypothesized that the extent of complement
activation might be a reliable predictor of mortality in this population. Forty-six
comatose cardiac arrest patients were enrolled into our prospective cohort study,
conducted in a tertiary care university clinic. All subjects were cooled to 32–
34 °C body temperature for 24 h and then allowed to rewarm to normothermia.
All patients underwent diagnostic coronary angiography. On admission, at 6 and
24 h, blood samples were taken from the arterial catheter. In these, complement
products (C3a, C3, C4d, C4, SC5b9 and Bb) were measured by ELISA in blood
samples. Patients were followed up for 30 days; 22 patients (47.8%) died by the
end of this period. We observed that complement activation (determined as the
C3a to C3 ratio) was higher in non-survivors than in survivors at each time point.
In the multivariate Cox regression analysis, the C3a/C3 ratio determined 24 h
after the initiation of therapeutic hypothermia predicted 30-day mortality
regardless of age, sex and the APACHE II score. Complement activation occurs
in post-cardiac arrest patients, and its extent correlates with 30-day survival. The
C3a/C3 ratio might prove useful for estimating the prognosis of comatose post-
cardiac arrest patients.
Introduction
Cardiac arrest causes generalized ischaemia/hypoxia, and
subsequent resuscitation inflicts reperfusion injury.
Although all the organs are damaged by hypoxia and
hypoperfusion, cerebral injury occurs first. This is because
the ischaemia tolerance and metabolic reserve of the brain
are limited, and hence, its functions are greatly dependent
on blood flow. Estimating the severity of brain damage and
predicting the prognosis of comatose, post-cardiac arrest
patients is a complex clinical challenge [1]. Nevertheless,
several promising methods are available to foretell neuro-
logical outcome, preferably using a multimodal prediction
approach [2]; however, further prognostic markers are
needed [3].
Complement is an important component of the humoral
immune system. It represents a highly effective means for
the destruction of invading micro-organisms, for the
elimination of immune complexes, as well as for the
clearance of damaged host cells. Complement is activated
by three pathways: the antibody-dependent classical
pathway, the alternative pathway or the recently discovered
ficolin-/mannose-binding lectin pathway [4]. Complement
activation leads to the formation of opsonins (C3b),
anaphylatoxins (C3a and C5a) and the cytolytic membrane
attack complex (C5b9) [5]. A large body of evidence from
the literature shows that complement activation plays an
important role in the pathophysiology of cell and tissue
damage after ischaemia and reperfusion [6]. The first report
on the activation of complement after cardiac arrest
appeared in 2002 [7]. Recently, Bisschops et al. [8]
confirmed this observation during mild therapeutic hypo-
thermia and rewarming. Several human ischaemic stroke
studies also reported complement activation [9–11].
Moreover, the genetic deficiency of mannose-binding lectin
(MBL) was associated with a better outcome after acute
stroke in mice and humans [12]. This indicates that
complement lectin pathway may play a crucial role in acute
brain ischaemia.
Our group demonstrated previously that complement
activation is associated with an unfavourable outcome after
acute ischaemic stroke [13] and chronic heart failure (CHF)
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[14]. Low ficolin-3 level is a major initiator of the ficolin–
lectin pathway in complement activation [15]. We also
showed a correlation between low ficolin-3 level, the
severity and the unfavourable outcome of acute ischaemic
stroke [16] and CHF [17]. We further presumed that as an
integrative marker of cellular damage, complement acti-
vation might be an independent predictor of mortality in
post-cardiac arrest patients. Accordingly, our study aimed
to describe the changes of complement proteins and
activation markers in post-cardiac arrest patients undergo-
ing mild therapeutic hypothermia and to analyse its
association with overall survival.
Materials and methods
Patient population, management and blood sampling. We
performed a prospective cohort study of 46 consecutive
comatose patients resuscitated after an out-of-hospital or an
in-hospital cardiac arrest. The patients were managed at the
Heart and Vascular Center, Semmelweis University,
Budapest. All patients aged 18 years or older were eligible
for inclusion, if they were comatose (Glasgow Coma Scale
score ≤6) after the restoration of spontaneous circulation.
Pregnant women were excluded along with patients who
received thrombolytic therapy or required at least two
vasopressors for refractory cardiogenic shock.
Intervention. All patients underwent diagnostic coronary
angiography and percutaneous coronary intervention (PCI),
where indicated. They were cooled to 32–34 °C by the
rapid infusion of 30 ml/kg body weight cold (4 °C)
lactated Ringer’s solution, followed by external cooling
with a water-circulating blanket (Blanketroll III, Cincin-
nati Subzero Medical Division, Cincinnati, OH, USA).
Their body temperature was maintained at 32–34 °C for
24 h, followed by re-warming at a rate of 0.25–0.33 °C/h
to normothermia (defined as core temperature ≥37 °C).
Survival data were recorded at discharge and at 30 days.
On admission to the intensive care unit [before the
initiation of hypothermia (i.e. at 0 h)], as well as 6 and
24 h later, blood samples were drawn from the arterial
catheter. All patients received antithrombotic and antico-
agulant therapy; contrast media were used only during
angiography. Blood samples [native and ethylenediamine-
tetraacetic acid (EDTA)] were centrifuged within 2 h (for
15 min at 2000 g and 25 °C), and the samples were stored
at 80 °C until analysis. Demographic, prehospital and
baseline data were collected on admission, whereas clinical
data were recorded continuously. The Acute Physiology
and Chronic Health Evaluation II (APACHE II) severity
score was calculated retrospectively, based on clinical data
from the initial 24 h.
The study was carried out in compliance with the
Helsinki Declaration. The study protocol was approved by
the local institutional review board (TUKEB), and written
informed consent was obtained from the closest relative.
Measurement of biomarkers. The complement activation
products C3a, C4d, SC5b9 and Bb were measured using
commercial enzyme-linked immunosorbent assays, accord-
ing to the manufacturer’s instructions (Quidel, San
Diego, CA, USA). To quantify C4 level, radial immu-
nodiffusion was performed using polyclonal rabbit anti-
human C4c (Dako, Glostrup, Denmark) and a human
serum protein calibrator (Dako) as described previously
[18]. C3 and total protein were determined with a Roche
Integra 800 (Basel, Switzerland) analyzer. C3, C4 and
total protein were measured in serum, while C3a, C4d,
SC5b9 and Bb were measured in EDTA plasma.
Correction for hemodilution. Total protein level in the
serum in post-cardiac arrest patients stayed low during
the initial 24 h, due to vigorous volume replacement upon
the initiation of hypothermia (rapid infusion of 30 ml/kg
body weight cold lactated Ringer’s solution). The medians
and interquartile ranges of total protein concentrations
were 60.3 (53.6–63.5), 55.3 (49.7–60.9) and 54.5 (48.3–
58.2) g/l, at 0, 6 and 24 h, respectively. Therefore, the
changes in total protein levels were used to normalize all
biomarker concentrations, to adjust for the influence of
excessive volume expansion. However, neither the C3a/C3
nor the C4d/C4 ratio required such correction, because of
the division.
Statistical analysis. Statistical analysis was performed
using GRAPHPAD PRISM version 5.0 (GraphPad Software, La
Jolla, CA, USA) and SPSS v13.0 (SPSS Inc., Chicago, IL,
USA). The data in the table are presented as medians, with
25th and 75th percentiles and ranges, because of their non-
normal distribution. Continuous variables were compared
between the two groups by Mann–Whitney’s U-test,
whereas Fisher’s exact test was applied to categorical
variables. The original data sets showed non-normal
distribution. Changes over time in the two subsets (of
survivors and of non-survivors) were analysed with two-
way repeated-measures ANOVA, and the Bonferroni post hoc
test was used in the case of log10 normalized data sets.
Normality was tested with QQ plot. Homogeneity of
variances was tested on the distribution of residuals. The
assumptions of ANOVA were not violated. Survival was
plotted according to the Kaplan–Meier method, and
differences in survival between the groups were compared
with log-rank tests. Univariate Cox proportional hazard
regressions were calculated to predict mortality. Thereafter,
the variable was fitted to multivariate Cox regression
models, to assess its effect on survival after adjustment for
covariates. The proportional hazards assumption was
confirmed by examining plots of Schoenfeld residuals.
The results of the Cox regression models are presented
as hazard ratios standardized on the SD of the predictors,
as well as the corresponding 95% CI, Wald v2 and P-
values of the likelihood-ratio tests. Two-tailed P-values
were calculated, and the significance level was set at
P < 0.05.
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Results
Baseline characteristics of the cohort
Forty-six comatose patients were enrolled after a cardiac
arrest. Twenty-two of them died within the first 30 days
(non-survivors), whereas 24 were alive after this period
(survivors). The median age and interquartile age range in
survivors and in non-survivors were 57 (47–66) and 66
(61–69) years (P = 0.014), respectively. The severity score
(APACHE II) was significantly lower in survivors than in
non-survivors P = 0.011, Mann–Whitney’s U-test. Both
groups (survivors and non-survivors) were dominated by
males (83% and 82%, P = 1.00) and characterized by a
high out-of-hospital cardiac arrest rate (71% and 86%,
P = 0.28, Fisher exact test). In our study, all patients
underwent diagnostic coronary angiography; 79.2% of the
survivors and 81.8% among non-survivors (P = 1.00,
Fisher exact test) received percutaneous coronary interven-
tion. Acute myocardial infarction was the underlying cause
of cardiac arrest in more than 85% of the subjects. The
cooling method was effective in both groups: the core
temperature of 34 °C was achieved in all patients of both
groups. The time from collapse to the start of ALS/BLS
(advanced/basic life support), the time from the collapse to
ROSC (return of spontaneous circulation) and the total
duration of CPR (cardiopulmonary resuscitation) were not
different between the groups of survivors and of non-
survivors (P = 0.62, P = 0.25, P = 0.49, respectively;
Mann–Whitney’s U-test). The body mass index was similar
in both groups (median 27.8 and 25.9 kg/m2, P = 0.71,
Mann–Whitney’s U-test).
Complement components and activation products in post-
cardiac arrest patients
First, we compared the levels of complement components
and activation products at three different time points: on
admission (0 h), as well as 6 and 24 h later, between the
groups (of survivors and non-survivors, stratified according
to 30-day survival), using repeated-measures ANOVA
(Table 1).
We observed a significant change in the levels of
complement activation products. Bb, sC5b9 and C3a/C3
ratio (a measure of C3 activation) decreased significantly
during the initial 24 h of therapeutic hypothermia
(Table 1, column ‘Time’).
Furthermore, we observed a consistently significant
difference in C3a/C3 ratio between the groups (of survivors
and of non-survivors), which suggests an association with
the outcome (Table 1, column ‘Group’). At each time
point, the C3a/C3 ratio was higher in non-survivors than in
survivors. The most important difference was observed at
24 h after the initiation of therapeutic hypothermia.
Accordingly, we used the 24-h data for further analysis
to assess the impact of the C3a/C3 ratio on survival. No
similar associations were observed in the case of any other
complement components or activation products (Table 1).
The relationship between complement activation and survival
Next, we analysed whether the activation of C3 is
associated with survival. The 46 patients were stratified
according to the median of C3a/C3 ratio (measured at
24 h), into low- or high-C3a/C3 ratio groups. Kaplan–
Meier survival analysis was carried out to evaluate
mortality over time in both groups (Fig. 1). In our cohort,
higher C3a/C3 ratio was associated with increased mortal-
ity (log-rank test, P = 0.0043, Fig. 1) during the 30-day-
long follow-up period. C3a/C3 ratio, age and the severity
score were also associated with 30-day mortality. Therefore,
we performed multivariate Cox proportional hazards
regression analysis to test the potential influence of
confounders on the predictive role of the C3a/C3 ratio.
In the univariate model, C3a/C3 ratio (considered as a
continuous, 1-SD standardized variable) significantly pre-
dicted 30-day mortality (hazard ratio 1.747, 95% CI
1.218–2.505 for 1-SD increase; Table 2). In the multivar-
iable Cox model, the prediction of 30-day mortality by the
C3a/C3 ratio was adjusted for age, sex and APACHE II
severity score. This parameter was an independent, signif-
icant predictor of mortality in adjusted models (hazard
ratio 1.692, 95% CI 1.105–2.590 for 1-SD increase;
Table 2). In summary, the C3a/C3 ratio predicts 30-day
mortality in post-cardiac arrest patients regardless of age,
sex and APACHE II severity score.
Discussion
The biochemical markers measured in blood samples can
serve as valid and useful predictors of clinical outcomes in
comatose cardiac arrest patients after successful resuscita-
tion [1]. Moreover, measuring such markers might prove
even more straightforward in everyday clinical practice
than neuroimaging or electrophysiological testing [1]. In
this study, we analysed for the first time whether the extent
of complement activation – as measured by the C3a/C3
ratio – is a reliable biomarker for predicting all-cause
mortality in comatose, resuscitated patients early, after the
first 24-h period.
We observed complement activation in post-cardiac
arrest patients and tested whether its extent is associated
with 30-day survival. In our study, complement C3a/C3
ratio – a marker of complement activation – predicted
short-term mortality (over 30 days) regardless of age, sex
and APACHE II severity score.
Complement activation was already observed earlier in
post-cardiac arrest patients [7, 8]. First, B€ottiger et al. [7]
reported significantly increased C3a and SC5b9 levels soon
after cardiac arrest. Next, Bisschops et al. showed remark-
Scandinavian Journal of Immunology, 2014, 79, 404–409
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able complement activation in post-cardiac arrest patients.
In particular, C3a, Bb and SC5b9 levels, which were
increased on admission, decreased gradually during the
mild hypothermia and increased again after rewarming [8].
In line with these observations, we found in the current
study major complement activation: the C3a/C3 ratio, as
well as Bb and sC5b9 levels decreased significantly both in
survivors and in non-survivors. The C3a/C3 ratio was
associated with the outcome, as it was markedly different
between the two groups. C3a activation has an important
role in overall complement activation. Accordingly, our
observation suggests that complement activation differs
between survivors and non-survivors, it is rather important
during the initial 24 h and it has a prognostic role.
Furthermore, we observed declining levels of complement
activation products (Bb and SC5b9); this might have been
linked to core temperature during therapeutic
Table 1 Levels of complement proteins and activation markers in post-cardiac arrest patients and the results of repeated-measures ANOVA. The patients
were stratified according to 30-day survival.
Original data sets
P-values of repeated-measures
ANOVA on the log10 normalized data
set
Parameters Time (h) All patients (n = 46) Survivors (n = 24) Non-survivors (n = 22) Group Time Interaction
C3a (ng/ml) 0 124.8 (97.1–239.3)a 120.9 (97.6–189.2) 148.4 (90.1–274.3) 0.104b 0.001 0.993
6 103.2 (80.3–156.4) 96.3 (80.7–112.6) 119.4 (73.1–162.2)
24 116.4 (79.4–176.3) 114.5 (80.4–122.9) 174.3 (76.3–196.3)
C3 (mg/ml) 0 1.06 (0.88–1.21) 1.11 (1.00–1.22) 1.01 (0.80–1.20) 0.063 0.007 0.014
6 1.08 (0.86–1.20) 1.11 (1.01–1.23) 0.94 (0.80–1.12)
24 1.15 (0.94–1.27) 1.16 (1.08–1.27) 1.02 (0.86–1.23)
C3a/C3 0 125.5 (86.8–215.6) 115.6 (85.4–196.1) 143.9 (106.4–281.0) 0.014 0.002 0.785
6 105.8 (74.0–157.8) 87.5 (72.6–124.2) 150.2 (91.2–173.7)
24 101.3 (77.4–172.5) 95.5 (73.2–116.7) 172.5 (82.3–207.2)
C4d (lg/ml) 0 1.7 (1.3–2.4) 1.8 (1.4–2.7) 1.5 (1.3–2.4) 0.834 0.146 0.643
6 2.0 (1.4–2.4) 2.1 (1.6–2.6) 1.9 (1.3–2.3)
24 1.8 (1.3–2.2) 1.8 (1.3–2.2) 2.0 (1.3–2.4)
C4 (mg/ml) 0 0.40 (0.31–0.49) 0.38 (0.30–0.50) 0.42 (0.33–0.48) 0.843 0.421 0.013
6 0.43 (0.28–0.48) 0.41 (0.28–0.46) 0.44 (0.27–0.49)
24 0.42 (0.31–0.48) 0.42 (0.34–0.50) 0.40 (0.28–0.43)
C4d/C4 0 4.4 (3.2–6.4) 5.6 (3.5–6.6) 4.1 (3.2–5.9) 0.938 0.084 0.204
6 4.9 (3.8–6.7) 5.2 (3.7–7.9) 4.7 (4.0–5.9)
24 4.4 (3.2–5.8) 4.1 (3.2–4.6) 4.8 (3.9–6.3)
Bb (lg/ml) 0 4.0 (2.1–8.5) 3.5 (2.1–7.0) 4.8 (2.3–9.4) 0.174 <0.001 0.676
6 2.1 (1.4–3.8) 1.8 (1.4–2.8) 2.7 (1.2–4.0)
24 1.2 (0.8–2.0) 1.2 (0.8–1.7) 1.9 (1.0–2.3)
sC5b9 (ng/ml) 0 342.9 (243.8–476.9) 363.6 (200.5–468.4) 312.3 (251.8–503.6) 0.582 <0.001 0.722
6 193.6 (142.8–269.5) 185.3 (151.1–260.3) 193.8 (141.3–269.5)
24 225.1 (156.4–285.4) 225.1 (162.3–285.4) 225.3 (153.8–263.1)
aMedian values and interquartile ranges.
bP-values of repeated-measures ANOVA are presented.
Figure 1 Kaplan–Meier survival plots in the two groups stratified
according to the median of the C3a/C3 ratio, measured 24 h after
admission. The P-value of log-rank test is indicated.
Table 2 Thirty-day mortality in post-cardiac arrest patients, as predicted
by the increased C3a/C3 ratio determined 24 h after the initiation of
therapeutic hypothermia.
Models HRa 95% CI v2 P-value
Univariate model of
C3a/C3 ratio
1.747 1.218–2.505 7.504 0.006
Multivariate model
of C3a/C3 ratio
adjusted for age, sex
and APACHE II score
1.692 1.105–2.590 5.249 0.022
aHR = Hazard ratio; HRs for variables shown as standardized hazard
ratios (HR per 1 SD increase of the variable where SD = 87.02) with 95%
CI; Wald v2 and P-values of likelihood-ratio tests are presented). C3a and
C3 levels used in the C3a/C3 ratio were measured 24 h after the initiation
of therapeutic hypothermia.
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hypothermia. As Bb (alternative pathway) and sC5b9
(terminal pathway) are only parts of the activation cascade
(in contrast to C3a, which has a central role in activation)
unsurprisingly, their levels were not associated with the
outcome.
Tissue necrosis or apoptotic cell death may be linked to
the observed complement activation. However, alternative
processes – such as those caused by severe hypoxia and
ischaemia, followed by reperfusion – may also contribute to
these reparatory and inflammatory processes. Remarkably,
Bisschops et al. considered ischaemic cardiomyopathy the
underlying cause of ventricular fibrillation in all of their
patients, none of which required coronary angiography or
percutaneous coronary intervention for myocardial infarc-
tion. On the contrary, all our patients underwent diagnos-
tic coronary angiography, and most of them required
percutaneous coronary intervention. Except for this differ-
ence, the major findings were rather similar between these
studies, namely, complement activation was present,
suggesting that it occurs regardless of the aetiology of
cardiac arrest.
We found that the C3a/C3 ratio was associated with
survival. Furthermore, we noticed a statistically significant
trend in the decrease of the C3a/C3 ratio both in survivors
and in non-survivors. This could have been linked to the
decrease in core temperature during therapeutic hypother-
mia (Table 1).
In view of the associations between the covariates (age,
sex, APACHE II severity score and C3a/C3 ratio) and
mortality, we performed Cox regression analysis to
investigate the potential influence of the former. We
established that the C3a/C3 ratio determined at 24 h is an
independent prognostic marker in post-cardiac arrest
patients. When added to the baseline predictive model
(age, sex and APACHE II severity score), the C3a/C3 ratio
achieved a significant and independent improvement of the
predictive model. This may indicate that the C3a/C3 ratio
is good additive marker of cell damage and injury to the
whole organism. Given the design of our study, it is
impossible to locate the source of complement activation.
We could not determine whether the C3a/C3 ratio is
simply a surrogate marker for the total duration of
ischaemia or else it reflects injury to specific organ
system (s).
A large body of evidence from the literature shows the
importance of complement activation in brain ischaemia,
both after ischaemic stroke [9–13, 16] and following a
cardiac arrest [7, 8]. Together, these studies confirm that
complement activation is detectable in various forms of
cerebral ischaemia. This marker could gain wide acceptance
as a prognostic index or a determinant of risk status in the
conditions mentioned herein.
Furthermore, amplification of the alternative pathway
appears to be another important factor in complement
activation in post-cardiac arrest patients. In this study, we
have shown that the C3a/C3 ratio, determined in blood
samples drawn soon after hospitalization, is suitable for the
prediction of prognosis also in a post-cardiac arrest
population.
Our study has its limitations, including the small
number of study subjects. However, the statistical power of
group estimations (Kaplan–Meier analysis) was sufficiently
high in the case of the C3a/C3 ratio and mortality
(Power = 0.79, at a = 0.05). Further, this was a single-
centre study, and therefore, its results should be considered
preliminary, until confirmed by independent studies.
Conclusions
Complement activation occurs in post-cardiac arrest
patients, and the C3a/C3 ratio is associated with 30-day
survival. The C3a/C3 ratio determined at 24 h predicted
30-day mortality regardless of age, sex and APACHE II
score. Therefore, it could prove useful for estimating the
prognosis of comatose post-cardiac arrest patients.
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